Deborah L Green1, Lisa Payne2, Robi Polikar3, Paul J Moberg4, David A Wolk5, John Kounios6. 1. Department of Psychology, Drexel University, Stratton Hall, 3141 Chestnut Street, Philadelphia, PA 19104, USA. Electronic address: Deborah.Green4@va.gov. 2. Volen National Center for Complex Systems, Brandeis University, 145 South Street, Waltham, MA 02453, USA. 3. Department of Electrical and Computer Engineering, Rowan University, 201 Mullica Hill Road, Glassboro, NJ 08028, USA. 4. Department of Neuropsychiatry, University of Pennsylvania, 10(th) floor, Gates Building, 3401 Spruce Street, Philadelphia, PA 19104, USA. 5. Department of Neurology, University of Pennsylvania, Ralston House, 3615 Chestnut Street, Philadelphia, PA 19104, USA. 6. Department of Psychology, Drexel University, Stratton Hall, 3141 Chestnut Street, Philadelphia, PA 19104, USA.
Abstract
INTRODUCTION: Reductions of cerebrospinal fluid (CSF) amyloid-beta (Aβ42) and elevated phosphorylated-tau (p-Tau) reflect in vivo Alzheimer's disease (AD) pathology and show utility in predicting conversion from mild cognitive impairment (MCI) to dementia. We investigated the P50 event-related potential component as a noninvasive biomarker of AD pathology in non-demented elderly. METHODS: 36 MCI patients were stratified into amyloid positive (MCI-AD, n=17) and negative (MCI-Other, n=19) groups using CSF levels of Aβ42. All amyloid positive patients were also p-Tau positive. P50s were elicited with an auditory oddball paradigm. RESULTS: MCI-AD patients yielded larger P50s than MCI-Other. The best amyloid-status predictor model showed 94.7% sensitivity, 94.1% specificity and 94.4% total accuracy. DISCUSSION: P50 predicted amyloid status in MCI patients, thereby showing a relationship with AD pathology versus MCI from another etiology. The P50 may have clinical utility for inexpensive pre-screening and assessment of Alzheimer's pathology. Published by Elsevier B.V.
INTRODUCTION: Reductions of cerebrospinal fluid (CSF) amyloid-beta (Aβ42) and elevated phosphorylated-tau (p-Tau) reflect in vivo Alzheimer's disease (AD) pathology and show utility in predicting conversion from mild cognitive impairment (MCI) to dementia. We investigated the P50 event-related potential component as a noninvasive biomarker of AD pathology in non-demented elderly. METHODS: 36 MCI patients were stratified into amyloid positive (MCI-AD, n=17) and negative (MCI-Other, n=19) groups using CSF levels of Aβ42. All amyloid positive patients were also p-Tau positive. P50s were elicited with an auditory oddball paradigm. RESULTS:MCI-ADpatients yielded larger P50s than MCI-Other. The best amyloid-status predictor model showed 94.7% sensitivity, 94.1% specificity and 94.4% total accuracy. DISCUSSION: P50 predicted amyloid status in MCI patients, thereby showing a relationship with AD pathology versus MCI from another etiology. The P50 may have clinical utility for inexpensive pre-screening and assessment of Alzheimer's pathology. Published by Elsevier B.V.
Authors: Oleg Korzyukov; Mark E Pflieger; Michael Wagner; Susan M Bowyer; T Rosburg; Karthik Sundaresan; Christian Erich Elger; Nashaat N Boutros Journal: Neuroimage Date: 2006-12-19 Impact factor: 6.556
Authors: Jason R Tregellas; Deana B Davalos; Donald C Rojas; Merilyne C Waldo; Linzi Gibson; Korey Wylie; Yiping P Du; Robert Freedman Journal: Schizophr Res Date: 2007-03-02 Impact factor: 4.939
Authors: Sanja Josef Golubic; Cheryl J Aine; Julia M Stephen; John C Adair; Janice E Knoefel; Selma Supek Journal: Hum Brain Mapp Date: 2017-07-17 Impact factor: 5.038
Authors: Sara Invitto; Giulia Piraino; Vincenzo Ciccarese; Laura Carmillo; Marcella Caggiula; Giorgio Trianni; Giuseppe Nicolardi; Santo Di Nuovo; Michela Balconi Journal: Front Aging Neurosci Date: 2018-09-13 Impact factor: 5.750